<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37024676</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-0064</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature reviews. Genetics</Title><ISOAbbreviation>Nat Rev Genet</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic lateral sclerosis: translating genetic discoveries into therapies.</ArticleTitle><Pagination><StartPage>642</StartPage><EndPage>658</EndPage><MedlinePgn>642-658</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41576-023-00592-y</ELocationID><Abstract><AbstractText>Recent advances in sequencing technologies and collaborative efforts have led to substantial progress in identifying the genetic causes of amyotrophic lateral sclerosis (ALS). This momentum has, in turn, fostered the development of putative molecular therapies. In this Review, we outline the current genetic knowledge, emphasizing recent discoveries and emerging concepts such as the implication of distinct types of mutation, variability in mutated genes in diverse genetic ancestries and gene-environment interactions. We also propose a high-level model to synthesize the interdependent effects of genetics, environmental and lifestyle factors, and ageing into a unified theory of ALS. Furthermore, we summarize the current status of therapies developed on the basis of genetic knowledge established for ALS over the past 30 years, and we discuss how developing treatments for ALS will advance our understanding of targeting other neurological diseases.</AbstractText><CopyrightInformation>&#xa9; 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ak&#xe7;imen</LastName><ForeName>Fulya</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0931-5247</Identifier><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA. fulya.akcimen@nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Elia R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Therapeutic Development Branch, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landers</LastName><ForeName>John E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nath</LastName><ForeName>Avindra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section of Infections of the Nervous System, National Institute for Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rita Levi Montalcini Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cognitive Sciences and Technologies, C.N.R, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azienda Ospedaliero Universitaria Citta' della Salute e della Scienza, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chia</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traynor</LastName><ForeName>Bryan J</ForeName><Initials>BJ</Initials><Identifier Source="ORCID">0000-0003-0527-2446</Identifier><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA. bryan.traynor@nih.gov.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Therapeutic Development Branch, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA. bryan.traynor@nih.gov.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University Medical Center, Baltimore, MD, USA. bryan.traynor@nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z01 AG000949</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Genet</MedlineTA><NlmUniqueID>100962779</NlmUniqueID><ISSNLinking>1471-0056</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059647" MajorTopicYN="N">Gene-Environment Interaction</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests. B.J.T. holds a patent on the diagnostic and therapeutic applications of the pathogenic repeat expansion in <i>C9orf72</i>. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>6</Day><Hour>23</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37024676</ArticleId><ArticleId IdType="doi">10.1038/s41576-023-00592-y</ArticleId><ArticleId IdType="pii">10.1038/s41576-023-00592-y</ArticleId><ArticleId IdType="pmc">PMC10611979</ArticleId><ArticleId IdType="mid">NIHMS1938894</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rowland LP &amp; Shneider NA Amyotrophic lateral sclerosis. N. Engl. J. Med 344, 1688&#x2013;1700 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar DR, Aslinia F, Yale SH &amp; Mazza JJ Jean-Martin Charcot: the father of neurology. Clin. Med. Res 9, 46&#x2013;49 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064755</ArticleId><ArticleId IdType="pubmed">20739583</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41, 118&#x2013;130 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L et al. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J. Neurol 267, 944&#x2013;953 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31797084</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration. Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee Meeting [online], https://www.youtube.com/watch?v=AVVZMMvDOUg (2022).</Citation></Reference><Reference><Citation>Arthur KC et al. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat. Commun 7, 12408 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4987527</ArticleId><ArticleId IdType="pubmed">27510634</ArticleId></ArticleIdList></Reference><Reference><Citation>Achtert K &amp; Kerkemeyer L The economic burden of amyotrophic lateral sclerosis: a systematic review. Eur. J. Health Econ 22, 1151&#x2013;1166 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34143346</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Gauthier A, Calvo A, Ghiglione P &amp; Mutani R Caregiver burden and patients&#x2019; perception of being a burden in ALS. Neurology 64, 1780&#x2013;1782 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15911811</ArticleId></ArticleIdList></Reference><Reference><Citation>Wicks P The ALS Ice Bucket Challenge &#x2013; can a splash of water reinvigorate a field? Amyotroph. Lateral Scler. Frontotemporal Degener 15, 479&#x2013;480 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25431828</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohn E Fundraising: the Ice Bucket Challenge delivers. Nature 550, S113&#x2013;S114 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29045371</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA et al. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol. 21, 465&#x2013;479 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9513754</ArticleId><ArticleId IdType="pubmed">35334234</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chio A &amp; Traynor BJ State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci 17, 17&#x2013;23 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller MF et al. Genome-wide analysis of the heritability of amyotrophic lateral sclerosis. JAMA Neurol. 71, 1123&#x2013;1134 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4566960</ArticleId><ArticleId IdType="pubmed">25023141</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J. Neurol. Neurosurg. Psychiatry 81, 1324&#x2013;1326 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2988617</ArticleId><ArticleId IdType="pubmed">20861059</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang F et al. Familial aggregation of amyotrophic lateral sclerosis. Ann. Neurol 66, 94&#x2013;99 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3609703</ArticleId><ArticleId IdType="pubmed">19670447</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, Chio A &amp; Traynor BJ Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 17, 94&#x2013;102 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez ER, Borschel WF &amp; Traynor BJ New antisense oligonucleotide therapies reach first base in ALS. Nat. Med 28, 25&#x2013;27 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35075291</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddique T et al. Linkage of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic-locus heterogeneity. N. Engl. J. Med 324, 1381&#x2013;1384 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2020294</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59&#x2013;62 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel O, Powell JF, Andersen PM &amp; Al-Chalabi A ALSoD: a user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum. Mutat 33, 1345&#x2013;1351 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22753137</ArticleId></ArticleIdList></Reference><Reference><Citation>McCann EP et al. Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis. J. Med. Genet 58, 87&#x2013;95 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32409511</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain 119, 1153&#x2013;1172 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8813280</ArticleId></ArticleIdList></Reference><Reference><Citation>Parton MJ et al. D90A-SOD1 mediated amyotrophic lateral sclerosis: a single founder for all cases with evidence for a Cis-acting disease modifier in the recessive haplotype. Hum. Mutat 20, 473 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12442272</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Turner MR, Ansorge O &amp; Talbot K Amyotrophic lateral sclerosis with a heterozygous D91A SOD1 variant and classical ALS-TDP neuropathology. Neurology 95, 595&#x2013;596 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32769137</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann. Neurol 41, 210&#x2013;221 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9029070</ArticleId></ArticleIdList></Reference><Reference><Citation>Berdynski M et al. Recurrent G41S mutation in Cu/Zn superoxide dismutase gene (SOD1) causing familial amyotrophic lateral sclerosis in a large Polish family. Amyotroph. Lateral Scler 13, 132&#x2013;136 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">21877919</ArticleId></ArticleIdList></Reference><Reference><Citation>Berdynski M et al. SOD1 mutations associated with amyotrophic lateral sclerosis analysis of variant severity. Sci. Rep 12, 103 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8742055</ArticleId><ArticleId IdType="pubmed">34996976</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzma-Kozakiewicz M et al. Putative founder effect in the Polish, Iranian and United States populations for the L144S SOD1 mutation associated with slowly uniform phenotype of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener 22, 80&#x2013;85 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32777948</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard E et al. Clinical and molecular landscape of ALS patients with SOD1 mutations: novel pathogenic variants and novel phenotypes. A single ALS center study. Int. J. Mol. Sci 21, 6807 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7554847</ArticleId><ArticleId IdType="pubmed">32948071</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamez J et al. Mutational analysis of the Cu/Zn superoxide dismutase gene in a Catalan ALS population: should all sporadic ALS cases also be screened for SOD1. J. Neurol. Sci 247, 21&#x2013;28 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16674979</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou L et al. Screening of SOD1, FUS and TARDBP genes in patients with amyotrophic lateral sclerosis in central-southern China. Sci. Rep 6, 32478 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5015023</ArticleId><ArticleId IdType="pubmed">27604643</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi Y, Homma K &amp; Ichijo H SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS. Adv. Biol. Regul 60, 95&#x2013;104 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26563614</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco DA et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat. Neurosci 13, 1396&#x2013;1403 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2967729</ArticleId><ArticleId IdType="pubmed">20953194</ArticleId></ArticleIdList></Reference><Reference><Citation>Raoul C et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med 11, 423&#x2013;428 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15768028</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralph GS et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med 11, 429&#x2013;433 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15768029</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RA et al. Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Invest 116, 2290&#x2013;2296 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1518790</ArticleId><ArticleId IdType="pubmed">16878173</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130&#x2013;133 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet 40, 572&#x2013;574 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319, 1668&#x2013;1672 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 12, 310&#x2013;322 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4565161</ArticleId><ArticleId IdType="pubmed">23415570</ArticleId></ArticleIdList></Reference><Reference><Citation>Besser LM, Teylan MA &amp; Nelson PT Limbic predominant age-related TDP-43 encephalopathy (LATE): clinical and neuropathological associations. J. Neuropathol. Exp. Neurol 79, 305&#x2013;313 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7036651</ArticleId><ArticleId IdType="pubmed">31845964</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk TR &amp; Rousseaux MWC The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol. Neurodegener 15, 45 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7429473</ArticleId><ArticleId IdType="pubmed">32799899</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 4, 124&#x2013;134 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23831027</ArticleId></ArticleIdList></Reference><Reference><Citation>Nomura T et al. Intranuclear aggregation of mutant FUS/TLS as a molecular pathomechanism of amyotrophic lateral sclerosis. J. Biol. Chem 289, 1192&#x2013;1202 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887186</ArticleId><ArticleId IdType="pubmed">24280224</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R et al. Superoxide dismutase 1 and tgSOD1 mouse spinal cord seed fibrils, suggesting a propagative cell death mechanism in amyotrophic lateral sclerosis. PLoS ONE 5, e10627 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2869360</ArticleId><ArticleId IdType="pubmed">20498711</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ Jr et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205&#x2013;1208 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208&#x2013;1211 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A et al. A de novo missense mutation of the FUS gene in a &#x201c;true&#x201d; sporadic ALS case. Neurobiol. Aging 32, 553 e523&#x2013;553 e556 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2972379</ArticleId><ArticleId IdType="pubmed">20598774</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N et al. FALS with FUS mutation in Japan, with early onset, rapid progress and basophilic inclusion. J. Hum. Genet 55, 252&#x2013;254 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20224596</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S, Rouleau GA &amp; Kabashi E TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. Hum. Mutat 34, 812&#x2013;826 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23559573</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubers A et al. De novo FUS mutations are the most frequent genetic cause in early-onset German ALS patients. Neurobiol. Aging 36, 3117 e3111&#x2013;3117 e3116 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26362943</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Shanware NP, Bowler MJ &amp; Tibbetts RS Amyotrophic lateral sclerosis-associated proteins TDP-43 and FUS/TLS function in a common biochemical complex to co-regulate HDAC6 mRNA. J. Biol. Chem 285, 34097&#x2013;34105 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2962508</ArticleId><ArticleId IdType="pubmed">20720006</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalfallah Y et al. TDP-43 regulation of stress granule dynamics in neurodegenerative disease-relevant cell types. Sci. Rep 8, 7551 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5953947</ArticleId><ArticleId IdType="pubmed">29765078</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco DA et al. Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. Hum. Mol. Genet 19, 4160&#x2013;4175 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2981014</ArticleId><ArticleId IdType="pubmed">20699327</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257&#x2013;268 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 11, 323&#x2013;330 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Dols-Icardo O et al. Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. Hum. Mol. Genet 23, 749&#x2013;754 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24057670</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebbert MTW et al. Long-read sequencing across the C9orf72 &#x2018;GGGGCC&#x2019; repeat expansion: implications for clinical use and genetic discovery efforts in human disease. Mol. Neurodegener 13, 46 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6102925</ArticleId><ArticleId IdType="pubmed">30126445</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende EL et al. Unravelling the clinical spectrum and the role of repeat length in C9ORF72 repeat expansions. J. Neurol. Neurosurg. Psychiatry 92, 502&#x2013;509 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8053328</ArticleId><ArticleId IdType="pubmed">33452054</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I et al. The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter. Mol. Psychiatry 21, 1112&#x2013;1124 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4960451</ArticleId><ArticleId IdType="pubmed">26481318</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordin A et al. Extensive size variability of the GGGGCC expansion in C9orf72 in both neuronal and non-neuronal tissues in 18 patients with ALS or FTD. Hum. Mol. Genet 24, 3133&#x2013;3142 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25712133</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck J et al. Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am. J. Hum. Genet 92, 345&#x2013;353 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3591848</ArticleId><ArticleId IdType="pubmed">23434116</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z et al. Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration. Proc. Natl Acad. Sci. USA 110, 7778&#x2013;7783 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651485</ArticleId><ArticleId IdType="pubmed">23553836</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77, 639&#x2013;646 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R &amp; Isaacs AM C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat. Rev. Neurol 14, 544&#x2013;558 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Fumagalli L et al. C9orf72-derived arginine-containing dipeptide repeats associate with axonal transport machinery and impede microtubule-based motility. Sci. Adv 7, eabg3013 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8034861</ArticleId><ArticleId IdType="pubmed">33837088</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat. Med 24, 313&#x2013;325 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramzon YA, Fratta P, Traynor BJ &amp; Chia R The overlapping genetics of amyotrophic lateral sclerosis and frontotemporal dementia. Front. Neurosci 14, 42 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7012787</ArticleId><ArticleId IdType="pubmed">32116499</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E et al. Repeat expansion in C9ORF72 in Alzheimer&#x2019;s disease. N. Engl. J. Med 366, 283&#x2013;284 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3513272</ArticleId><ArticleId IdType="pubmed">22216764</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenna KP et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat. Genet 48, 1037&#x2013;1042 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5560030</ArticleId><ArticleId IdType="pubmed">27455347</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A et al. Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron 97, 1268&#x2013;1283 e1266 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D et al. Hot-spot KIF5A mutations cause familial ALS. Brain 141, 688&#x2013;697 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837483</ArticleId><ArticleId IdType="pubmed">29342275</ArticleId></ArticleIdList></Reference><Reference><Citation>Saez-Atienzar S et al. Identification of a pathogenic intronic KIF5A mutation in an ALS&#x2013;FTD kindred. Neurology 95, 1015&#x2013;1018 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7734922</ArticleId><ArticleId IdType="pubmed">33077544</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron DM et al. ALS-associated KIF5A mutations abolish autoinhibition resulting in a toxic gain of function. Cell Rep. 39, 110598 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9134378</ArticleId><ArticleId IdType="pubmed">35385738</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellanos-Montiel MJ, Chaineau M &amp; Durcan TM The neglected genes of ALS: cytoskeletal dynamics impact synaptic degeneration in ALS. Front. Cell Neurosci 14, 594975 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7691654</ArticleId><ArticleId IdType="pubmed">33281562</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenting G, Laura F &amp; Ludo Van Den B in Amyotrophic Lateral Sclerosis (ed. Hegde LM) (IntechOpen, 2020).</Citation></Reference><Reference><Citation>Tunca C et al. ERLIN1 mutations cause teenage-onset slowly progressive ALS in a large Turkish pedigree. Eur. J. Hum. Genet 26, 745&#x2013;748 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5945623</ArticleId><ArticleId IdType="pubmed">29453415</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu ZY et al. A novel homozygous mutation in ERLIN1 gene causing spastic paraplegia 62 and literature review. Eur. J. Med. Genet 65, 104608 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36100157</ArticleId></ArticleIdList></Reference><Reference><Citation>Novarino G et al. Exome sequencing links corticospinal motor neuron disease to common neurodegenerative disorders. Science 343, 506&#x2013;511 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4157572</ArticleId><ArticleId IdType="pubmed">24482476</ArticleId></ArticleIdList></Reference><Reference><Citation>Egorova PA &amp; Bezprozvanny IB Inositol 1,4,5-trisphosphate receptors and neurodegenerative disorders. FEBS J. 285, 3547&#x2013;3565 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29253316</ArticleId></ArticleIdList></Reference><Reference><Citation>Higo T et al. Mechanism of ER stress-induced brain damage by IP3 receptor. Neuron 68, 865&#x2013;878 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">21145001</ArticleId></ArticleIdList></Reference><Reference><Citation>Casey JP et al. A novel gain-of-function mutation in the ITPR1 suppressor domain causes spinocerebellar ataxia with altered Ca2+ signal patterns. J. Neurol 264, 1444&#x2013;1453 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28620721</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhan SMK et al. Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat-shock protein. Nat. Neurosci 22, 1966&#x2013;1974 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6919277</ArticleId><ArticleId IdType="pubmed">31768050</ArticleId></ArticleIdList></Reference><Reference><Citation>Jih KY, Tsai PC, Tsai YS, Liao YC &amp; Lee YC Rapid progressive ALS in a patient with a DNAJC7 loss-of-function mutation. Neurol. Genet 6, e503 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7524575</ArticleId><ArticleId IdType="pubmed">33062890</ArticleId></ArticleIdList></Reference><Reference><Citation>He J et al. Validation of the pathogenic role of rare DNAJC7 variants in Chinese patients with amyotrophic lateral sclerosis. Neurobiol. Aging 106, 314 e311&#x2013;314 e316 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34233860</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M et al. A novel potentially pathogenic rare variant in the DNAJC7 gene identified in amyotrophic lateral sclerosis patients from mainland China. Front. Genet 11, 821 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7476650</ArticleId><ArticleId IdType="pubmed">33193563</ArticleId></ArticleIdList></Reference><Reference><Citation>Tohnai G et al. Mutation screening of the DNAJC7 gene in Japanese patients with sporadic amyotrophic lateral sclerosis. Neurobiol. Aging 113, 131&#x2013;136 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35039179</ArticleId></ArticleIdList></Reference><Reference><Citation>Dilliott AA et al. DnaJC7 in amyotrophic lateral sclerosis. Int. J. Mol. Sci 23, 4076 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9025444</ArticleId><ArticleId IdType="pubmed">35456894</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinwal UK et al. Cdc37/Hsp90 protein complex disruption triggers an autophagic clearance cascade for TDP-43 protein. J. Biol. Chem 287, 24814&#x2013;24820 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3397908</ArticleId><ArticleId IdType="pubmed">22674575</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewan R et al. Pathogenic huntingtin repeat expansions in patients with frontotemporal dementia and amyotrophic lateral sclerosis. Neuron 109, 448&#x2013;460 e444 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7864894</ArticleId><ArticleId IdType="pubmed">33242422</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman RA et al. Amyotrophic lateral sclerosis is over-represented in two Huntington&#x2019;s disease brain bank cohorts: further evidence to support genetic pleiotropy of pathogenic HTT gene expansion. Acta Neuropathol. 143, 105&#x2013;108 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8918027</ArticleId><ArticleId IdType="pubmed">34800149</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewan R et al. CAG somatic instability in a Huntington disease expansion carrier presenting with a progressive supranuclear palsy-like phenotype. Mov. Disord 37, 1555&#x2013;1557 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9308656</ArticleId><ArticleId IdType="pubmed">35510647</ArticleId></ArticleIdList></Reference><Reference><Citation>Grima JC et al. Mutant huntingtin disrupts the nuclear pore complex. Neuron 94, 93&#x2013;107 e106 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5595097</ArticleId><ArticleId IdType="pubmed">28384479</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature 525, 129&#x2013;133 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi SJ et al. Targeting huntingtin expression in patients with Huntington&#x2019;s disease. N. Engl. J. Med 380, 2307&#x2013;2316 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31059641</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO et al. Association of variants in the SPTLC1 gene with juvenile amyotrophic lateral sclerosis. JAMA Neurol. 78, 1236&#x2013;1248 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8406220</ArticleId><ArticleId IdType="pubmed">34459874</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohassel P et al. Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis. Nat. Med 27, 1197&#x2013;1204 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9309980</ArticleId><ArticleId IdType="pubmed">34059824</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejaoui K et al. SPTLC1 is mutated in hereditary sensory neuropathy, type 1. Nat. Genet 27, 261&#x2013;262 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11242106</ArticleId></ArticleIdList></Reference><Reference><Citation>Penno A et al. Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. J. Biol. Chem 285, 11178&#x2013;11187 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856995</ArticleId><ArticleId IdType="pubmed">20097765</ArticleId></ArticleIdList></Reference><Reference><Citation>Garofalo K et al. Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. J. Clin. Invest 121, 4735&#x2013;4745 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3225995</ArticleId><ArticleId IdType="pubmed">22045570</ArticleId></ArticleIdList></Reference><Reference><Citation>Buniello A et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 47, D1005&#x2013;D1012 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323933</ArticleId><ArticleId IdType="pubmed">30445434</ArticleId></ArticleIdList></Reference><Reference><Citation>Schymick JC et al. Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 6, 322&#x2013;328 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17362836</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat. Genet 41, 1083&#x2013;1087 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19734901</ArticleId></ArticleIdList></Reference><Reference><Citation>Laaksovirta H et al. Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. Lancet Neurol. 9, 978&#x2013;985 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965392</ArticleId><ArticleId IdType="pubmed">20801718</ArticleId></ArticleIdList></Reference><Reference><Citation>Shatunov A et al. Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurol. 9, 986&#x2013;994 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3257853</ArticleId><ArticleId IdType="pubmed">20801717</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet 48, 1043&#x2013;1048 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Benyamin B et al. Cross-ethnic meta-analysis identifies association of the GPX3&#x2013;TNIP1 locus with amyotrophic lateral sclerosis. Nat. Commun 8, 611 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5606989</ArticleId><ArticleId IdType="pubmed">28931804</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat. Genet 53, 1636&#x2013;1648 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8648564</ArticleId><ArticleId IdType="pubmed">34873335</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogh I et al. A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. Hum. Mol. Genet 23, 2220&#x2013;2231 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959809</ArticleId><ArticleId IdType="pubmed">24256812</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura R et al. A multi-ethnic meta-analysis identifies novel genes, including ACSL5, associated with amyotrophic lateral sclerosis. Commun. Biol 3, 526 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7511394</ArticleId><ArticleId IdType="pubmed">32968195</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli ET et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 347, 1436&#x2013;1441 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci 18, 631&#x2013;636 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D et al. NEK1 mutations in familial amyotrophic lateral sclerosis. Brain 139, e28 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26945885</ArticleId></ArticleIdList></Reference><Reference><Citation>Saez-Atienzar S et al. Genetic analysis of amyotrophic lateral sclerosis identifies contributing pathways and cell types. Sci. Adv 7, eabd9036 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7810371</ArticleId><ArticleId IdType="pubmed">33523907</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho WY et al. The ALS-FTD-linked gene product, C9orf72, regulates neuronal morphogenesis via autophagy. Autophagy 15, 827&#x2013;842 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6526867</ArticleId><ArticleId IdType="pubmed">30669939</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M et al. A C9ORF72/SMCR8-containing complex regulates ULK1 and plays a dual role in autophagy. Sci. Adv 2, e1601167 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5010369</ArticleId><ArticleId IdType="pubmed">27617292</ArticleId></ArticleIdList></Reference><Reference><Citation>Maekawa S et al. Cortical selective vulnerability in motor neuron disease: a morphometric study. Brain 127, 1237&#x2013;1251 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15130949</ArticleId></ArticleIdList></Reference><Reference><Citation>Maniatis S et al. Spatiotemporal dynamics of molecular pathology in amyotrophic lateral sclerosis. Science 364, 89&#x2013;93 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30948552</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphrey J et al. Integrative transcriptomic analysis of the amyotrophic lateral sclerosis spinal cord implicates glial activation and suggests new risk genes. Nat. Neurosci 26, 150&#x2013;162 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36482247</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H et al. Multi-omic analysis of selectively vulnerable motor neuron subtypes implicates altered lipid metabolism in ALS. Nat. Neurosci 24, 1673&#x2013;1685 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8639773</ArticleId><ArticleId IdType="pubmed">34782793</ArticleId></ArticleIdList></Reference><Reference><Citation>Tazelaar GHP et al. ATXN1 repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalization. Brain Commun. 2, fcaa064 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7425293</ArticleId><ArticleId IdType="pubmed">32954321</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466, 1069&#x2013;1075 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Daoud H et al. Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis. Arch. Neurol 68, 739&#x2013;742 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21670397</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass JD et al. ATXN2 intermediate expansions in amyotrophic lateral sclerosis. Brain 145, 2671&#x2013;2676 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9890463</ArticleId><ArticleId IdType="pubmed">35521889</ArticleId></ArticleIdList></Reference><Reference><Citation>Blauw HM et al. NIPA1 polyalanine repeat expansions are associated with amyotrophic lateral sclerosis. Hum. Mol. Genet 21, 2497&#x2013;2502 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22378146</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Khleifat A et al. Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis. NPJ Genom. Med 7, 8 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8799638</ArticleId><ArticleId IdType="pubmed">35091648</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross JP, Dion PA &amp; Rouleau GA in Spectrums of Amyotrophic Lateral Sclerosis (eds Shaw CA &amp; Morrice JR) 17&#x2013;34 (Wiley, 2021).</Citation></Reference><Reference><Citation>Valdmanis PN et al. A mutation that creates a pseudoexon in SOD1 causes familial ALS. Ann. Hum. Genet 73, 652&#x2013;657 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19847927</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan S et al. A comprehensive analysis of rare genetic variation in amyotrophic lateral sclerosis in the UK. Brain 140, 1611&#x2013;1618 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5445258</ArticleId><ArticleId IdType="pubmed">28430856</ArticleId></ArticleIdList></Reference><Reference><Citation>Eitan C et al. Whole-genome sequencing reveals that variants in the Interleukin 18 Receptor Accessory Protein 3&#x2019;UTR protect against ALS. Nat. Neurosci 25, 433&#x2013;445 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7614916</ArticleId><ArticleId IdType="pubmed">35361972</ArticleId></ArticleIdList></Reference><Reference><Citation>Birve A et al. A novel SOD1 splice site mutation associated with familial ALS revealed by SOD activity analysis. Hum. Mol. Genet 19, 4201&#x2013;4206 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20709807</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawata A et al. Aberrant splicing of human Cu/Zn superoxide dismutase (SOD1) RNA transcripts. Neuroreport 11, 2649&#x2013;2653 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10976937</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong YH et al. Tdp-43 cryptic exons are highly variable between cell types. Mol. Neurodegener 12, 13 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5289002</ArticleId><ArticleId IdType="pubmed">28153034</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling JP, Pletnikova O, Troncoso JC &amp; Wong PC TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science 349, 650&#x2013;655 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AL et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature 603, 131&#x2013;137 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander MD et al. &#x201c;True&#x201d; sporadic ALS associated with a novel SOD-1 mutation. Ann. Neurol 52, 680&#x2013;683 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12402272</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller K et al. De novo mutations in SOD1 are a cause of ALS. J. Neurol. Neurosurg. Psychiatry 93, 201&#x2013;206 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8784989</ArticleId><ArticleId IdType="pubmed">34518333</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Montojo M, Doucet-O&#x2019;Hare T, Henderson L &amp; Nath A Human endogenous retrovirus-K (HML-2): a comprehensive review. Crit. Rev. Microbiol 44, 715&#x2013;738 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6342650</ArticleId><ArticleId IdType="pubmed">30318978</ArticleId></ArticleIdList></Reference><Reference><Citation>MacGowan DJ et al. A controlled study of reverse transcriptase in serum and CSF of HIV-negative patients with ALS. Neurology 68, 1944&#x2013;1946 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17536052</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W et al. Human endogenous retrovirus-K contributes to motor neuron disease. Sci. Transl. Med 7, 307ra153 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6344353</ArticleId><ArticleId IdType="pubmed">26424568</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Montojo M et al. Inhibition of HERV-K (HML-2) in amyotrophic lateral sclerosis patients on antiretroviral therapy. J. Neurol. Sci 423, 117358 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8009857</ArticleId><ArticleId IdType="pubmed">33653604</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts GD et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat. Genet 36, 377&#x2013;381 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15034582</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 68, 857&#x2013;864 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032425</ArticleId><ArticleId IdType="pubmed">21145000</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A et al. Cognitive impairment across ALS clinical stages in a population-based cohort. Neurology 93, e984&#x2013;e994 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6745732</ArticleId><ArticleId IdType="pubmed">31409738</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 70, 1004&#x2013;1009 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Khalik J et al. Defective cholesterol metabolism in amyotrophic lateral sclerosis. J. Lipid Res 58, 267&#x2013;278 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5234729</ArticleId><ArticleId IdType="pubmed">27811233</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge JC et al. Neutral lipid cacostasis contributes to disease pathogenesis in amyotrophic lateral sclerosis. J. Neurosci 40, 9137&#x2013;9147 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7673008</ArticleId><ArticleId IdType="pubmed">33051352</ArticleId></ArticleIdList></Reference><Reference><Citation>Andres-Benito P et al. Lipid alterations in human frontal cortex in ALS-FTLD-TDP43 proteinopathy spectrum are partly related to peroxisome impairment. Neuropathol. Appl. Neurobiol 47, 544&#x2013;563 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8248144</ArticleId><ArticleId IdType="pubmed">33332650</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Hirayama T, Takazawa T, Kawabe K &amp; Iwasaki Y Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern. Med 51, 1501&#x2013;1508 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22728481</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, Talbot K &amp; Turner MR Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 93, 75&#x2013;81 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8685635</ArticleId><ArticleId IdType="pubmed">34518331</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler RG, Pedersen WA, Camandola S, Rothstein JD &amp; Mattson MP Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann. Neurol 52, 448&#x2013;457 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12325074</ArticleId></ArticleIdList></Reference><Reference><Citation>Theofilopoulos S et al. Cholestenoic acids regulate motor neuron survival via liver X receptors. J. Clin. Invest 124, 4829&#x2013;4842 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4347238</ArticleId><ArticleId IdType="pubmed">25271621</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge JC et al. Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA 112, 8100&#x2013;8105 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4491749</ArticleId><ArticleId IdType="pubmed">26056266</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amico E et al. Metabolic abnormalities, dietary risk factors and nutritional management in amyotrophic lateral sclerosis. Nutrients 13, 2273 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8308334</ArticleId><ArticleId IdType="pubmed">34209133</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A et al. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology 73, 1681&#x2013;1685 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19917991</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang JW et al. Hypolipidemia in patients with amyotrophic lateral sclerosis: a possible gender difference? J. Clin. Neurol 9, 125&#x2013;129 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3633190</ArticleId><ArticleId IdType="pubmed">23626651</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutedja NA et al. Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 82, 638&#x2013;642 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21471184</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann H, Ho WY, Chang JC &amp; Ling SC Cholesterol dyshomeostasis in amyotrophic lateral sclerosis: cause, consequence, or epiphenomenon? FEBS J. 289, 7688&#x2013;7709 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34469619</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasta R, Chia R, Traynor BJ &amp; Chio A Unraveling the complex interplay between genes, environment, and climate in ALS. EBioMedicine 75, 103795 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8728044</ArticleId><ArticleId IdType="pubmed">34974309</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandres-Ciga S et al. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann. Neurol 85, 470&#x2013;481 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450729</ArticleId><ArticleId IdType="pubmed">30723964</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA et al. Metabolomics identifies shared lipid pathways in independent amyotrophic lateral sclerosis cohorts. Brain 145, 4425&#x2013;4439 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9762943</ArticleId><ArticleId IdType="pubmed">35088843</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng P, Wang T, Zheng J &amp; Zhou X Causal association of type 2 diabetes with amyotrophic lateral sclerosis: new evidence from Mendelian randomization using GWAS summary statistics. BMC Med. 17, 225 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6892209</ArticleId><ArticleId IdType="pubmed">31796040</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Tang L, Huang T &amp; Fan D Association between type 2 diabetes and amyotrophic lateral sclerosis. Sci. Rep 12, 2544 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8847454</ArticleId><ArticleId IdType="pubmed">35169211</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H et al. Type 2 diabetes mellitus and amyotrophic lateral sclerosis: genetic overlap, causality, and mediation. J. Clin. Endocrinol. Metab 106, e4497&#x2013;e4508 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34171091</ArticleId></ArticleIdList></Reference><Reference><Citation>Julian TH et al. A review of Mendelian randomization in amyotrophic lateral sclerosis. Brain 145, 832&#x2013;842 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9050546</ArticleId><ArticleId IdType="pubmed">34791088</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ovidio F et al. The role of pre-morbid diabetes on developing amyotrophic lateral sclerosis. Eur. J. Neurol 25, 164&#x2013;170 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">28921834</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakken O, Meyer HE, Stigum H &amp; Holmoy T High BMI is associated with low ALS risk: a population-based study. Neurology 93, e424&#x2013;e432 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31243073</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasta R, D&#x2019;Ovidio F, Logroscino G &amp; Chio A The links between diabetes mellitus and amyotrophic lateral sclerosis. Neurol. Sci 42, 1377&#x2013;1387 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7955983</ArticleId><ArticleId IdType="pubmed">33544228</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid E et al. A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am. J. Hum. Genet 71, 1189&#x2013;1194 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC385095</ArticleId><ArticleId IdType="pubmed">12355402</ArticleId></ArticleIdList></Reference><Reference><Citation>Crimella C et al. Mutations in the motor and stalk domains of KIF5A in spastic paraplegia type 10 and in axonal Charcot&#x2013;Marie-Tooth type 2. Clin. Genet 82, 157&#x2013;164 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">21623771</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin S, Hardiman O &amp; Traynor BJ Ethnic variation in the incidence of ALS: a systematic review. Neurology 68, 1002&#x2013;1007 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17389304</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou ZY et al. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 88, 540&#x2013;549 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Pliner HA, Mann DM &amp; Traynor BJ Searching for Grendel: origin and global spread of the C9ORF72 repeat expansion. Acta Neuropathol. 127, 391&#x2013;396 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4545603</ArticleId><ArticleId IdType="pubmed">24496499</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Nishiyama A, Warita H &amp; Aoki M Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy. J. Hum. Genet 68, 131&#x2013;152 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9968660</ArticleId><ArticleId IdType="pubmed">35691950</ArticleId></ArticleIdList></Reference><Reference><Citation>Dombroski BA et al. C9orf72 hexanucleotide repeat expansion and Guam amyotrophic lateral sclerosis-Parkinsonism-dementia complex. JAMA Neurol. 70, 742&#x2013;745 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3771869</ArticleId><ArticleId IdType="pubmed">23588498</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G &amp; Piccininni M Amyotrophic lateral sclerosis descriptive epidemiology: the origin of geographic difference. Neuroepidemiology 52, 93&#x2013;103 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30602169</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A et al. Large proportion of amyotrophic lateral sclerosis cases in Sardinia due to a single founder mutation of the TARDBP gene. Arch. Neurol 68, 594&#x2013;598 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3513278</ArticleId><ArticleId IdType="pubmed">21220647</ArticleId></ArticleIdList></Reference><Reference><Citation>Chadi G et al. Genetic analysis of patients with familial and sporadic amyotrophic lateral sclerosis in a Brazilian Research Center. Amyotroph. Lateral Scler. Frontotemporal Degener 18, 249&#x2013;255 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27978769</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO et al. Exome sequencing reveals riboflavin transporter mutations as a cause of motor neuron disease. Brain 135, 2875&#x2013;2882 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3437022</ArticleId><ArticleId IdType="pubmed">22740598</ArticleId></ArticleIdList></Reference><Reference><Citation>Green P et al. Brown&#x2013;Vialetto&#x2013;Van Laere syndrome, a ponto-bulbar palsy with deafness, is caused by mutations in c20orf54. Am. J. Hum. Genet 86, 485&#x2013;489 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2833371</ArticleId><ArticleId IdType="pubmed">20206331</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandres-Ciga S, Noyce AJ &amp; Traynor BJ Mendelian randomization &#x2014; a journey from obscurity to center stage with a few potholes along the way. JAMA Neurol. 77, 7&#x2013;8 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31609383</ArticleId></ArticleIdList></Reference><Reference><Citation>Pingault JB et al. Using genetic data to strengthen causal inference in observational research. Nat. Rev. Genet 19, 566&#x2013;580 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29872216</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebbert MTW, Lank RJ &amp; Belzil VV An epigenetic spin ALS FTD. Adv. Neurobiol 20, 1&#x2013;29 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29916014</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett SA, Tanaz R, Cobos SN &amp; Torrente MP Epigenetics in amyotrophic lateral sclerosis: a role for histone post-translational modifications in neurodegenerative disease. Transl. Res 204, 19&#x2013;30 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6331271</ArticleId><ArticleId IdType="pubmed">30391475</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolinar A, Ravnik-Glavac M &amp; Glavac D Epigenetic mechanisms in amyotrophic lateral sclerosis: a short review. Mech. Ageing Dev 174, 103&#x2013;110 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29545202</ArticleId></ArticleIdList></Reference><Reference><Citation>Hop PJ et al. Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Sci. Transl. Med 14, eabj0264 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10040186</ArticleId><ArticleId IdType="pubmed">35196023</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan CT et al. C9orf72 promoter hypermethylation is neuroprotective: neuroimaging and neuropathologic evidence. Neurology 84, 1622&#x2013;1630 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4409587</ArticleId><ArticleId IdType="pubmed">25795648</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O et al. Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann. Neurol 77, 75&#x2013;99 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4432483</ArticleId><ArticleId IdType="pubmed">25381879</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman KJ Causes. Am. J. Epidemiol 104, 587&#x2013;592 (1976).</Citation><ArticleIdList><ArticleId IdType="pubmed">998606</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfahad T &amp; Nath A Retroviruses and amyotrophic lateral sclerosis. Antivir. Res 99, 180&#x2013;187 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3723705</ArticleId><ArticleId IdType="pubmed">23707220</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, Robberecht W &amp; Van Den Bosch L Modelling amyotrophic lateral sclerosis: progress and possibilities. Dis. Model. Mech 10, 537&#x2013;549 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5451175</ArticleId><ArticleId IdType="pubmed">28468939</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 13, 1108&#x2013;1113 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4197338</ArticleId><ArticleId IdType="pubmed">25300936</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ &amp; Singleton AB Nature versus nurture: death of a dogma, and the road ahead. Neuron 68, 196&#x2013;200 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2974322</ArticleId><ArticleId IdType="pubmed">20955927</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle EA, Li YI &amp; Pritchard JK An expanded view of complex traits: from polygenic to omnigenic. Cell 169, 1177&#x2013;1186 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5536862</ArticleId><ArticleId IdType="pubmed">28622505</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L &amp; Meininger V A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med 330, 585&#x2013;591 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing G &amp; Edaravone, A. L. S. S. G. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 16, 505&#x2013;512 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med 377, 1723&#x2013;1732 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>Sufit RL, Ajroud-Driss S, Casey P &amp; Kessler JA Open label study to assess the safety of VM202 in subjects with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener 18, 269&#x2013;278 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28166654</ArticleId></ArticleIdList></Reference><Reference><Citation>Korobeynikov VA, Lyashchenko AK, Blanco-Redondo B, Jafar-Nejad P &amp; Shneider NA Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat. Med 28, 104&#x2013;116 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8799464</ArticleId><ArticleId IdType="pubmed">35075293</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullard A ALS antisense drug falters in phase III. Nat. Rev. Drug Discov 20, 883&#x2013;885 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34716445</ArticleId></ArticleIdList></Reference><Reference><Citation>Biogen Investor Relations. New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benefit in People With SOD1-ALS [Online], https://investors.biogen.com/news-releases/news-release-details/new-12-month-tofersen-data-presented-encals-meeting-show (2022).</Citation></Reference><Reference><Citation>Tabrizi SJ et al. Potential disease-modifying therapies for Huntington&#x2019;s disease: lessons learned and future opportunities. Lancet Neurol. 21, 645&#x2013;658 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7613206</ArticleId><ArticleId IdType="pubmed">35716694</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M et al. Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study. Neurotherapeutics 19, 1248&#x2013;1258 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9587202</ArticleId><ArticleId IdType="pubmed">35585374</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran H et al. Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide. Nat. Med 28, 117&#x2013;124 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8861976</ArticleId><ArticleId IdType="pubmed">34949835</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544, 367&#x2013;371 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan JM et al. Convective forces increase rostral delivery of intrathecal radiotracers and antisense oligonucleotides in the cynomolgus monkey nervous system. J. Transl. Med 18, 309 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7414676</ArticleId><ArticleId IdType="pubmed">32771027</ArticleId></ArticleIdList></Reference><Reference><Citation>Belov V et al. Large-volume intrathecal administrations: impact on CSF pressure and safety implications. Front. Neurosci 15, 604197 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8079755</ArticleId><ArticleId IdType="pubmed">33935624</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts TC, Langer R &amp; Wood MJA Advances in oligonucleotide drug delivery. Nat. Rev. Drug Discov 19, 673&#x2013;694 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7419031</ArticleId><ArticleId IdType="pubmed">32782413</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata T et al. Cholesterol-functionalized DNA/RNA heteroduplexes cross the blood&#x2013;brain barrier and knock down genes in the rodent CNS. Nat. Biotechnol 39, 1529&#x2013;1536 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34385691</ArticleId></ArticleIdList></Reference><Reference><Citation>Gennemark P et al. An oral antisense oligonucleotide for PCSK9 inhibition. Sci. Transl. Med 13, eabe9117 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33980578</ArticleId></ArticleIdList></Reference><Reference><Citation>Figlewicz DA et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum. Mol. Genet 3, 1757&#x2013;1761 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7849698</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat. Genet 29, 160&#x2013;165 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11586297</ArticleId></ArticleIdList></Reference><Reference><Citation>Puls I et al. Mutant dynactin in motor neuron disease. Nat. Genet 33, 455&#x2013;456 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12627231</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura AL et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am. J. Hum. Genet 75, 822&#x2013;831 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182111</ArticleId><ArticleId IdType="pubmed">15372378</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YZ et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am. J. Hum. Genet 74, 1128&#x2013;1135 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182077</ArticleId><ArticleId IdType="pubmed">15106121</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinson N et al. ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B). Neurology 67, 1074&#x2013;1077 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16807408</ArticleId></ArticleIdList></Reference><Reference><Citation>Skibinski G et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat. Genet 37, 806&#x2013;808 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16041373</ArticleId></ArticleIdList></Reference><Reference><Citation>Orlacchio A et al. SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. Brain 133, 591&#x2013;598 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2822627</ArticleId><ArticleId IdType="pubmed">20110243</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465, 223&#x2013;226 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng HX et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477, 211&#x2013;215 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169705</ArticleId><ArticleId IdType="pubmed">21857683</ArticleId></ArticleIdList></Reference><Reference><Citation>Fecto F et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch. Neurol 68, 1440&#x2013;1446 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22084127</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CH et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature 488, 499&#x2013;503 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575525</ArticleId><ArticleId IdType="pubmed">22801503</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 495, 467&#x2013;473 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756911</ArticleId><ArticleId IdType="pubmed">23455423</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BN et al. Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. Neuron 84, 324&#x2013;331 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521390</ArticleId><ArticleId IdType="pubmed">25374358</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat. Neurosci 17, 664&#x2013;666 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4000579</ArticleId><ArticleId IdType="pubmed">24686783</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannwarth S et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain 137, 2329&#x2013;2345 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4107737</ArticleId><ArticleId IdType="pubmed">24934289</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KL et al. CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nat. Commun 7, 11253 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4835537</ArticleId><ArticleId IdType="pubmed">27080313</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BN et al. Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Sci. Transl. Med 9, eaad9157 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6599403</ArticleId><ArticleId IdType="pubmed">28469040</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J et al. Mutations in the glycosyltransferase domain of GLT8D1 are associated with familial amyotrophic lateral sclerosis. Cell Rep. 26, 2298&#x2013;2306 e2295 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7003067</ArticleId><ArticleId IdType="pubmed">30811981</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassano M et al. Systematic evaluation of genetic mutations in ALS: a population-based study. J. Neurol. Neurosurg. Psychiatry 93, 1190&#x2013;1193 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9606529</ArticleId><ArticleId IdType="pubmed">35896380</ArticleId></ArticleIdList></Reference><Reference><Citation>McCann EP et al. The genotype-phenotype landscape of familial amyotrophic lateral sclerosis in Australia. Clin. Genet 92, 259&#x2013;266 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28105640</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BN et al. The C9ORF72 expansion mutation is a common cause of ALS+/&#x2212; FTD in Europe and has a single founder. Eur. J. Hum. Genet 21, 102&#x2013;108 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3522204</ArticleId><ArticleId IdType="pubmed">22692064</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittrup A &amp; Lieberman J Knocking down disease: a progress report on siRNA therapeutics. Nat. Rev. Genet 16, 543&#x2013;552 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4756474</ArticleId><ArticleId IdType="pubmed">26281785</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahryari A et al. Development and clinical translation of approved gene therapy products for genetic disorders. Front. Genet 10, 868 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773888</ArticleId><ArticleId IdType="pubmed">31608113</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok A, Raulf N &amp; Habib N Developing small activating RNA as a therapeutic: current challenges and promises. Ther. Deliv 10, 151&#x2013;164 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30909853</ArticleId></ArticleIdList></Reference><Reference><Citation>Wengert ER et al. Targeted augmentation of nuclear gene output (TANGO) of Scn1a rescues parvalbumin interneuron excitability and reduces seizures in a mouse model of Dravet Syndrome. Brain Res. 1775, 147743 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34843701</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders R
FDA approves first test of CRISPR to correct genetic defect causing sickle cell disease [online], https://news.berkeley.edu/2021/03/30/fda-approves-first-test-ofcrispr-to-correct-genetic-defect-causing-sickle-cell-disease/ (2021).</Citation></Reference><Reference><Citation>Frangoul H et al. CRISPR&#x2013;Cas9 gene editing for sickle cell disease and beta-thalassemia. N. Engl. J. Med 384, 252&#x2013;260 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33283989</ArticleId></ArticleIdList></Reference><Reference><Citation>No authors listed. FDA approves hereditary blindness gene therapy. Nat. Biotechnol 36, 6 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29319697</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Related links</Title><Reference><Citation>Answer ALS: https://www.answerals.org/</Citation></Reference><Reference><Citation>Clinical trial information for Engensis (VM202): https://alsnewstoday.com/vm202/</Citation></Reference><Reference><Citation>dbGaP: https://www.ncbi.nlm.nih.gov/gap/</Citation></Reference><Reference><Citation>N=1 Collaborative network: https://www.n1collaborative.org/</Citation></Reference><Reference><Citation>New York Genome Center ALS Consortium: https://www.nygenome.org/als-consortium/</Citation></Reference><Reference><Citation>Online Mendelian Inheritance in Man: https://www.omim.org/</Citation></Reference><Reference><Citation>Project MinE: https://www.projectmine.com/</Citation></Reference><Reference><Citation>Safety study of VM202 to treat amyotrophic lateral sclerosis: https://clinicaltrials.gov/ct2/show/NCT02039401</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>